VIP - Lymphoma patients
The population is composed of lymphoma patients, aged 18 years and older, who intend to receive the COVID-19 vaccine or have received the COVID-19 vaccine at any time in the past.
The population is composed of lymphoma patients, aged 18 years and older, who intend to receive the COVID-19 vaccine or have received the COVID-19 vaccine at any time in the past.
-
Minimum age
-
18
-
Newborns
-
-
Twins
-
-
Countries
-
-
Territory
-
Edmonton, Montreal, Ottawa, Toronto
-
Ethnic Origin
-
-
Health Status
-
Participants are diagnosed with lymphoma.
Participants are excluded if they have chronic myelogenous leukemia, myeloproliferative neoplasm not on cytoreductive therapy, or any absolute contraindications to the COVID-19 vaccine.
-
Other Criteria
-
Participants are excluded if they received an autologous stem cell transplantation (autoSCT) or allogeneic hematopoietic stem cell transplantation (alloSCT) treatment for non-hematologic malignancy diseases.
Participants are included if they were never treated for lymphoma, previously treated with anti-CD20 (>1 month since last treatment dose), currently receiving anti-CD20 treatment, or if they are receiving non-antiCD20 treatment (<1 month since last treatment dose).
-
Supplementary Information about selection criteria
-
-
Sources of recruitment
-
-
Specific Population
-
-
Supplementary Information
-
Participants are recruited in hematology clinics from one of twelve participating hospitals around Canada.
-
Number of Participants
-
378
-
Number of Participants with Biological Samples
-
378